Back to FEDERATED HERMES, INC. FEDERATED HERMES, INC.

RARERARE
29 quarters

Position history for FEDERATED HERMES, INC.FEDERATED HERMES, INC.'s holdings in Ultragenyx Pharmaceutical, Inc.

FEDERATED HERMES, INC. previously held 0 shares of RARE (Ultragenyx Pharmaceutical, Inc.), worth $0 as of 2025-Q4.

Final Value

$0

Final Shares

0

Total Value Change

-$55.5M

Total Shares Change

-1.3M

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2025-Q4
Latest
Exited
0
-100.0%
$00.0%$22.78
0
2025-Q3
Decreased
496,060
-75.8%
$14.9M0.0%$30.36
0
2025-Q2
Decreased
2M
-0.3%
$74.5M0.1%$36.52
0
2025-Q1
Increased
2.1M
+0.3%
$74.4M0.2%$37.82
35
2024-Q4
Decreased
2M
-2.9%
$86.2M0.2%$42.27
0
2024-Q3
Increased
2.1M
+0.2%
$117.2M0.3%$54.43
36
2024-Q2
Increased
2.1M
+8.7%
$86.6M0.2%$41.10
39
2024-Q1
Decreased
1.9M
-20.8%
$90.5M0.2%$46.69
0
2023-Q4
Increased
2.4M
+11.4%
$117M0.3%$47.82
40
2023-Q3
Increased
2.2M
+23.6%
$78.3M0.2%$35.65
43
2023-Q2
Decreased
1.8M
-29.7%
$82M0.2%$46.65
0
2023-Q1
Decreased
2.5M
-18.4%
$101.3M0.3%$38.64
0
2022-Q4
Decreased
3.1M
-18.9%
$143.4M0.4%$46.33
0
2022-Q3
Increased
3.8M
+0.5%
$158M0.5%$40.55
36
2022-Q2
Decreased
3.8M
-4.8%
$226.5M0.6%$60.24
0
2022-Q1
Increased
4M
+0.0%
$289.6M0.7%$71.36
43
2021-Q4
Decreased
4M
0.0%
$335.3M0.6%$84.25
0
2021-Q3
Increased
4M
+3.5%
$359.6M0.7%$86.12
45
2021-Q2
Decreased
3.9M
-1.6%
$367.2M0.7%$96.29
0
2021-Q1
Decreased
3.9M
-8.6%
$445.5M0.9%$112.06
0
2020-Q4
Increased
4.3M
+4.5%
$592.6M1.2%$144.37
52
2020-Q3
Increased
4.1M
+0.3%
$336.5M0.8%$85.10
44
2020-Q2
Increased
4.1M
+1.6%
$319.2M0.8%$73.66
44
2020-Q1
Increased
4M
+35.1%
$178.5M0.5%$44.32
56
2019-Q4
Increased
3M
+4.1%
$126.9M0.3%$42.69
38
2019-Q3
Increased
2.9M
+60.8%
$122.1M0.3%$42.50
52
2019-Q2
Increased
1.8M
+1.4%
$112.7M0.3%$63.50
36
2019-Q1
Increased
1.7M
+37.0%
$121.3M0.3%$69.36
47
2018-Q4
New
1.3M
-
$55.5M0.2%$41.87
49

Other major holders of RARE: Capital Research Global Investors, BNP PARIBAS FINANCIAL MARKETS, Capital International Investors

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used